US FDA approves GSK’s AREXVY, the world’s first respiratory …
WEBMay 3, 2023 · Respiratory syncytial virus vaccine, adjuvanted, contains a recombinant subunit prefusion RSV F glycoprotein antigen (RSVPreF3) combined with GSK’s proprietary AS01 E adjuvant. In the US, AREXVY is indicated for the prevention of RSV-LRTD in individuals 60 years of age and older.
GSK RSV shot 43% effective against severe disease in third year
WEB2 days ago · Oct 8 (Reuters) - GSK (GSK.L) said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in its third season after patients received the ...
US FDA approves expanded age indication for GSK’s AREXVY, the …
WEBJun 7, 2024 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved AREXVY (Respiratory Syncytial Virus (RSV) Vaccine, Adjuvanted) for the prevention of RSV lower respiratory tract disease (LRTD) in adults 50 through 59 years of age who are at increased risk.
GSK announces AREXVY, its respiratory syncytial virus (RSV) …
WEBAug 17, 2023 · Shared clinical decision making empowers patients, in consultation with their healthcare providers, to decide whether RSV vaccination is appropriate for them. AREXVY is indicated for the prevention of RSV-lower respiratory tract disease (LRTD) in individuals aged 60 years and older.
US FDA approves GSK’s Arexvy, the world’s first respiratory …
WEBMay 3, 2023 · US FDA approves GSK’s Arexvy, the world’s first respiratory syncytial virus (RSV) vaccine for older adults. Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time. The approval is based on data from the positive pivotal AReSVi-006 phase III trial that showed exceptional efficacy ...
RSV vaccine race heats up with highly effective GSK shot
WEBOct 13, 2022 · Data unveiled on Thursday showed GSK's respiratory syncytial virus (RSV) vaccine was 82.6% effective in a keenly watched late-stage study involving older adults.
GSK RSV vaccine shows potential to protect adults 50 to 59
WEBOct 25, 2023 · A vaccine from GlaxoSmithKline showed the potential to protect adults ages 50 to 59 from respiratory syncytial virus in a late-stage clinical trial. The preliminary trial results suggest that...
FDA approves RSV vaccine for adults ages 60 and up - NBC News
WEBMay 3, 2023 · The Food and Drug Administration on Wednesday approved the world's first RSV vaccine: a shot for adults ages 60 and up, made by pharmaceutical giant GSK. The milestone was decades in the making....
GSK Says RSV Vaccine Offers Protection Over Three Seasons
WEB2 days ago · 1:42. GSK Plc’s shot for respiratory syncytial virus provided protection across three seasons after vaccination, the company said Tuesday. The shot for older adults showed cumulative efficacy ...
FDA advisers recommend world's first RSV vaccines, from ... - NBC News
WEBMar 1, 2023 · Food and Drug Administration advisers recommended this week that the agency approve two RSV vaccines for older people, one from Pfizer and another from GlaxoSmithKline.